# Global Organ-on-Chip Market Size, Share, Trends and Forecast 2026-2036 | Set to Reach $2.5 Billion as Regulatory Acceptance and Animal Testing Alternatives Drive 22.2% CAGR

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/global-organ-on-chip-market-size-share-trends-and-forecast-2026-2036-set-to-reach-2-5-bill/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Regulatory tailwinds and demand for animal-free testing boost opportunities in multi-organ platforms, precision medicine, CRO services, and Asia-Pacific*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6288424/organ-on-chip-market-global-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ls55nx&amp;utm_campaign=2399894+-+Global+Organ-on-Chip+Market+Size%2c+Share%2c+Trends+and+Forecast+2026-2036+%7c+Set+to+Reach+%242.5+Billion+as+Regulatory+Acceptance+and+Animal+Testing+Alternatives+Drive+22.2%25+CAGR&amp;utm_exec=jocamsai" rel="nofollow">"Organ-on-Chip Market - Global Forecast to 2036"</a> has been added to **ResearchAndMarkets.com's** offering.

The global Organ-on-Chip market is projected to reach $2.5 billion by 2036, expanding at a CAGR of 22.2% from 2026 to 2036. Market growth is being driven by increasing demand for alternatives to animal testing, rising drug discovery R&D costs, and growing regulatory acceptance of microphysiological systems as preclinical evidence.

Favorable policy and funding developments are also creating substantial opportunities for Organ-on-Chip market participants. The FDA Modernization Act 2.0 removed the statutory requirement for animal-based safety and efficacy data, while expanding NIH investment continues to support tissue chip technologies. These developments, combined with demand for human-relevant preclinical models, are accelerating adoption across pharmaceutical research, biotechnology, toxicology, and disease modeling.

The report provides historical market data for 2025, estimated market data for 2026, and forecasts through 2036. It evaluates the market by organ type, type, product & service, technology, cell source, application, end user, and geography.

**Key Segment Insights**

-   **Organ type:** The Liver-on-Chip segment is expected to account for the largest market share in 2026. Its leadership reflects the liver's central role in drug metabolism and the high incidence of drug-induced toxicity, making these models important for hepatotoxicity and drug metabolism studies. Multi-Organ-on-Chip platforms are projected to record the fastest growth as pharmaceutical companies increase their focus on systemic drug distribution and inter-organ toxicity.
-   **Type:** The Single-Organ-on-Chip segment is expected to lead the market in 2026 due to its established validation base and broader adoption in drug screening and toxicology. Human-on-Chip platforms are forecast to grow at the fastest rate, supported by investment in systemic physiological models designed to represent whole-body drug responses.
-   **Product & service:** Products are projected to hold the largest market share in 2026, driven by investment in Organ-on-Chip devices and instrumentation among pharmaceutical companies and research institutions. Services are expected to register the fastest growth as biotechnology companies and research organizations seek contract testing capabilities without significant upfront capital expenditure.
-   **Application:** Drug Discovery & Development is projected to remain the largest application segment in 2026, supported by the use of Organ-on-Chip technology in target validation, drug screening, and pharmacokinetic studies. Personalized & Precision Medicine is expected to grow most rapidly as patient-derived cell-based models gain traction for predicting individual treatment responses.
-   **End user:** Pharmaceutical & Biotechnology Companies are expected to represent the largest end-user segment in 2026 as Organ-on-Chip systems become more integrated into preclinical development pipelines. Contract Research Organizations are projected to achieve the fastest growth due to increased outsourcing of testing and disease modeling services.

**Regional Organ-on-Chip Market Outlook**

North America is expected to account for the largest share of the Organ-on-Chip market in 2026. Growth in the region is supported by leading technology developers, substantial NIH funding through the Tissue Chip for Drug Screening program, and a more direct regulatory pathway for incorporating Organ-on-Chip data into U.S. drug development submissions.

Asia-Pacific is projected to register the highest CAGR during 2026-2036. Key growth factors include expanding pharmaceutical and biotechnology R&D investment in China, Japan, South Korea, and India; strengthening academic expertise in microfluidics and tissue engineering; and increasing government support for advanced life sciences research infrastructure.

**Competitive Landscape**

Key companies operating in the Organ-on-Chip market include Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd. (U.K.), TissUse GmbH (Germany), InSphero AG (Switzerland), Nortis, Inc. (U.S.), AlveoliX AG (Switzerland), Hesperos, Inc. (U.S.), Kirkstall Ltd. (U.K.), Cherry Biotech (France), AIM Biotech Pte. Ltd. (Singapore), SynVivo, Inc. (U.S.), Quris-AI (Israel), and Altis Biosystems, Inc. (U.S.).

**Key Questions Addressed in the Report**

-   What revenue is currently generated by the global Organ-on-Chip market, and how quickly will demand grow through 2036?
-   Which regulatory, technological, and commercial factors are influencing market growth at regional and country levels?
-   Which organ types, technologies, cell sources, applications, products, services, and end users offer the strongest opportunities?
-   Which regions and countries are expected to provide significant expansion opportunities for established companies and new entrants?
-   Who are the leading Organ-on-Chip market participants, and what products and services do they offer?
-   How are recent strategic developments affecting competition and long-term market growth?

For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6288424/organ-on-chip-market-global-forecast?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=ls55nx&amp;utm_campaign=2399894+-+Global+Organ-on-Chip+Market+Size%2c+Share%2c+Trends+and+Forecast+2026-2036+%7c+Set+to+Reach+%242.5+Billion+as+Regulatory+Acceptance+and+Animal+Testing+Alternatives+Drive+22.2%25+CAGR&amp;utm_exec=jocamsai" rel="nofollow">https://www.researchandmarkets.com/r/4g7ytn</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/MWI2OTNlOWItZDllYy00MmYwLWI0MjctNmE2Njg3NzI2YjhhLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Global Bariatric Surgery Devices Market Analysis and Forecast to 2036 | Expected to Reach US$3.42 Billion as Robotic, Endoscopic, and Revisional Procedures Drive Growth Amid GLP-1 Disruption](https://healthcarenews.io/news/global-bariatric-surgery-devices-market-analysis-and-forecast-to-2036-expected-to-reach-us.md)
- [Global Medical AI Apps Market Size and Forecast by Application, End Use and Region (2026-2033) | 19.1% CAGR Fueled by Digital Health and Personalized Care](https://healthcarenews.io/news/global-medical-ai-apps-market-size-and-forecast-by-application-end-use-and-region-2026-203.md)
- [Cell Line Development - Global Strategic Business Report 2026-2032: Capitalize on 10.1% CAGR](https://healthcarenews.io/news/cell-line-development-global-strategic-business-report-2026-2032-capitalize-on-10-1-cagr.md)
- [Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding](https://healthcarenews.io/news/dare-bioscience-receives-approximately-852-000-in-additional-grant-funding.md)
